

SESSIONS

ON-DEMAND SESSIONS -

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Drug discovery models to prioritize pathways and targets for Parkinson's disease

On demand

AI Applications for Drug Discovery Development

- Discuss attempted methods for generative chemistry and virtual screening
- Implementation of data mining techniques to identify alternative indications for drugs in pipeline

[Watch Case Study](#)

Participants

Speaker: **Andy Lee** - COO, Vincere Biosciences

Many Shots on Goal: Evotec's Business Model

On demand

BioPharm America: Innovation and Investing

This series of fireside chats features different models of innovation, why they work, and how they contribute to the biotech ecosystem. In this chat, Thomas Hanke from Evotec's BRIDGES initiative will discuss some of the different partnerships that drive early innovation.

[Watch Session](#)

Participants

Host: **Stephanie Marrus** - Managing Director, Entrepreneurship, UCSF

Guest: **Thomas Hanke** - EVP, Head of Academic Partnerships, Evotec

BioPharm America Startup Pitch Competition

12:00am - 1:00am

Startup Pitch Competition

Qualifying startup companies have been invited to pitch their company using no more than four slides and four minutes. Our panel of judges will determine the winner by the quality and effectiveness of the pitch.

Participating Companies:

- Ardan Pharma
- Ciscovery Bio Inc.
- Element Therapeutics
- EndoCrine
- MediGear International Corp

[View Competition](#)

[Meet the Judges](#)

Participants

Judge: **Mira Chaurushiya** - Partner, 5AM Ventures

Judge: **Anjali Kumar** - Sr. Director External Innovation Search and Evaluation, Johnson & Johnson Innovation

Judge: **Matthew Miessau** - Associate, Epidarex

Judge: **Anna Turetsky** - Principal, Venture Investments, The Mark Foundation for Cancer Research

What will it take to succeed in drug delivery - A look into what's coming

On demand - Coming Soon

Drug Delivery Partnerships

Participants

Speaker: **Cornell Stamoran** - VP, Corporate Strategy, Catalent Pharma Solutions

HealthMyne

On demand

Interviews

Deborah Gravelle, Content Marketing Manager at EBD Group interviews Rose Higgins, CEO at HealthMyne.

[Watch Interview](#)

Participants

Interviewer: **Deborah Gravelle** - Content Marketing Manager, EBD Group

Interviewee: **Rose Higgins** - CEO, HealthMyne

Targeting the morphological impact of disease

On demand - Coming Soon

AI Applications for Drug Discovery Development

Participants

Speaker: **Marzieh Haghighi** - Postdoctoral Associate, Broad Institute of MIT and Harvard

The IndieBio Accelerator Model

On demand

BioPharm America: Innovation and Investing

This series of fireside chats features different models of innovation, why they work, and how they contribute to the biotech ecosystem. In this chat, Stephen Chambers from IndieBio will discuss the role accelerators play in the biotech ecosystem.

[Watch Session](#)

Participants

Host: **Stephanie Marrus** - Managing Director, Entrepreneurship, UCSF

Guest: **Stephen Chambers** - Managing Director, IndieBio NY

Building Consumer Healthcare (OTC) Brands with Novel Drug Delivery in 2020

On demand

Drug Delivery Partnerships

[Watch Presentation](#)

Participants

Speaker: **Bob Nissen** - President, Nissen Consulting

The Digital Story: How Bayer is Playing It

On demand

BioPharm America: Innovation and Investing

This series of fireside chats features different models of innovation, why they work, and how they contribute to the biotech ecosystem. In this chat, Douglas Lee discusses how digital innovation, internally and externally, is developing in tandem with biotech business models.

[Watch Session](#)

Participants

Host: **Stephanie Marrus** - Managing Director, Entrepreneurship, UCSF

Guest: **Douglas Lee** - VP, Head Digital and Data Science, Business Development & Licensing, Bayer

Drug Delivery Partnerships Posters

On demand

Drug Delivery Partnerships

[View Posters](#)

Pharma Open Innovation: Bayer's Case Study

On demand

BioPharm America: Innovation and Investing

This series of fireside chats features different models of innovation, why they work, and how they contribute to the biotech ecosystem. In this chat, Chandra Ramanathan discusses a global approach to sourcing and supporting biotech innovation.

[Watch Session](#)

Participants

Host: **Stephanie Marrus** - Managing Director, Entrepreneurship, UCSF

Guest: **Chandra Ramanathan** - Global Head, Pharma R&D Open Innovation, Bayer

Challenging the norms of early stage investment

On demand

BioPharm America: Innovation and Investing

This series of fireside chats explores models of financial support and financing for biotech startups and early stage companies. Speakers will identify the key elements, financial and otherwise, needed to ensure a stable foundation for future growth and development of biotech companies and the therapeutics they deliver to patients.

[Watch Session](#)

Participants

Host: **Steve Dickman** - CEO, CBT Advisors

Guest: **Jürgen Eckhardt** - CEO, Leaps by Bayer

SESSIONS

ON-DEMAND SESSIONS -

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Alternative venture strategies for early stage funding

On demand

BioPharm America: Innovation and Investing

This series of talks explores models of financial support and financing for biotech startups and early stage companies. Speakers will identify the key elements, financial and otherwise, needed to ensure a stable foundation for future growth and development of biotech companies and the therapeutics they deliver to patients.

[Watch Session](#)

Participants

Host: Steve Dickman - CEO, CBT Advisors

Guest: Kevin Johnson - Co-Founder and Partner, Medicxi

Early stage funding trends in Europe

On demand

BioPharm America: Innovation and Investing

This series of talks explores models of financial support and financing for biotech startups and early stage companies. Speakers will identify the key elements, financial and otherwise, needed to ensure a stable foundation for future growth and development of biotech companies and the therapeutics they deliver to patients.

[Watch Session](#)

Participants

Host: Steve Dickman - CEO, CBT Advisors

Guest: Regina Hodits - General Partner, Wellington Partners Life Sciences

Fostering diversity in and through biotech investment

On demand

BioPharm America: Innovation and Investing

[Watch Panel](#)

Participants

Moderator: Elliott Francis - Director, Diversity and Inclusion, BIO (Biotechnology Innovation Organization)

Panelist: Celia Economides - Senior VP, Strategy and External Affairs, Kezar Life Sciences

Panelist: Paul Hastings - CEO, Nkarta Therapeutics

Panelist: Sara Nayeem - Partner, NEA

Catalyzing Innovation Partnerships in a COVID-19 Era

On demand

BioPharm America: Innovation and Investing

The world has changed in 2020, making partnerships to accelerate healthcare innovation more important than ever. Since the start of the COVID-19 pandemic, transformation to the innovation ecosystem is enabling and accelerating early scientific discoveries by investing and partnering with innovators with the potential to positively impact human health. In this fireside chat, leaders from Johnson & Johnson Innovation share insights and perspectives about catalyzing innovation partnerships in the COVID-19 era, along with Thirty Madison's CEO Steven Gutentag and Polaris Partners' Managing Partner Amy Schulman.

[Watch Panel](#)

Participants

Moderator: Julie Hamill - Sr. Director, External Innovation Strategy and Programs, Johnson & Johnson Innovation

Panelist: Stacy Feld - Head, Johnson & Johnson Innovation, West North America, Australia & New Zealand, Johnson & Johnson Innovation

Panelist: Steven Gutentag - CEO and Co-Founder, Thirty Madison

Panelist: Amy Schulman - Managing Partner, Polaris Partners

SCHEDULE

ON-DEMAND SESSIONS -

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

TIME	AI APPLICATIONS FOR DRUG DISCOVERY DEVELOPMENT	BIOPHARM AMERICA: INNOVATION AND INVESTING	DRUG DELIVERY PARTNERSHIPS	INTERVIEWS	STARTUP PITCH COMPETITION
12:00AM	<p>On demand - Drug discovery models to prioritize pathways and targets for Parkinson's disease</p> <p>On demand - Coming Soon - Targeting the morphological impact of disease</p>	<p>On demand - Many Shots on Goal: Evotec's Business Model</p> <p>On demand - The Indiebio Accelerator Model</p> <p>On demand - The Digital Story: How Bayer is Playing It</p>	<p>On demand - Coming Soon - What will it take to succeed in drug delivery - A look into what's coming</p> <p>On demand - Building Consumer Healthcare (OTC) Brands with Novel Drug Delivery in 2020</p> <p>On demand - Drug Delivery Partnerships Posters</p>	<p>On demand - HealthMyne</p>	<p>12:00am - BioPharm America Startup Pitch Competition</p>
1:00AM		<p>On demand - Pharma Open Innovation: Bayer's Case Study</p> <p>On demand - Challenging the norms of early stage investment</p> <p>On demand - Alternative venture strategies for early stage funding</p>			
2:00AM		<p>On demand - Early stage funding trends in Europe</p> <p>On demand - Fostering diversity in and through biotech investment</p>			
3:00AM		<p>On demand - Catalyzing Innovation Partnerships in a COVID-19 Era</p>			

Agilex Biolabs

On demand
BioPharm America Presentations

Agilex Biolabs, Australia's leading bioanalytical laboratory, has 20 years' experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of pre-clinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and potential to qualify for the R&D rebate of more than 40% on all work conducted in Australia.

Our bioanalytical facilities have OECD GLP recognition with NATA and ISO 17025 Accreditation with NATA. Technical work is performed to meet FDA and EMA guidelines, providing our clients with a globally accepted basis for drug approval. Our client base includes leading pharmaceutical and biotech companies in Asia, Europe and the USA.

When you partner with Agilex Biolabs, you can be confident that your project will be delivered by the experts on time and with the highest quality results.

[Watch Video](#)

Participants

Presenter: Jason Valentine - CEO, Agilex Biolabs

ARDAN PHARMA

On demand
Startup Presentations

Pursuing new targets and mechanisms implied in cancer progression, we develop novel immunotherapies that harness the power of inflammation.

[View Pitch](#)

Aprecia - Delivering the Next Generation of Medicine Today

On demand
Drug Delivery Partnerships Presentations

[Watch Video](#)

Participants

Presenter: Kirk Donaldson - VP of Business Development and Alliance Management, Aprecia

Ciscovery Bio Inc

On demand
Startup Presentations

We develop gene regulatory elements in the non-coding genome as (1) non-coding biomarkers for drug discovery and (2) toolkits for gene therapy.

[View Pitch](#)

Anima Biotech

On demand
BioPharm America Presentations

Anima Biotech is pioneering Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against undruggable proteins. With our proprietary technology that emits light pulses from ribosomes, we identify drug candidates that selectively decrease or increase the translation of proteins and elucidate their mechanism of action in a new target space. Our pipeline includes programs in Fibrosis (tissue selective Collagen I translation inhibitors), Oncology (cMyc translation inhibitors), RSV (viral translation inhibitors) and Huntington's disease (selective inhibition of the mutant mHTT) and our \$1B partnership with Lilly around several Neuroscience targets. Our science was further validated with 5 granted patents, 15 peer reviewed publications and 17 scientific collaborations.

[Watch Video](#)

Participants

Presenter: Yochi Slonim - Co-founder & CEO, Board member, AnimaBiotech

Element Therapeutics Company

On demand
Startup Presentations

Development of therapeutics needs for Central Nervous System (CNS) Disorders & substance use disorder (SUD).

[View Pitch](#)

Key Tech & Matchstick - Foundational Methods to Confidently Freeze Complex Delivery Device Architectures

On demand
Drug Delivery Partnerships Presentations

[Watch Video](#)

Participants

Presenter: Mariano Mumpower - Senior Mechanical Engineer, Key Technologies

Presenter: Brian Costello - Senior Strategist, Matchstick, LLC

EndoCrine

On demand
Startup Presentations

EndoCrine is working on providing transformational therapies for patients with diabetes. Current therapeutics only treat the symptoms (hyperglycemia) without eliminating the underlying cause of the disease. Born out of years of cutting-edge stem cell research at UCSF and seasoned by the UCSF Entrepreneurship center, EndoCrine aims to change the paradigm of diabetes therapeutics from that of managing the symptoms to one that offers a cure. Utilizing our revolutionary technology to produce millions of insulin producing cells from human stem cells, we have established a platform to discover novel biologics that help the patient's body preserve insulin secretion and regenerate its own insulin cells.

[View Pitch](#)

API Co., Ltd

On demand
BioPharm America Presentations

API Co., Ltd. is a food and pharmaceutical company, headquartered in Gifu, Japan. Recently we have developed a novel humanized anti-podoplanin mAb for treating osteosarcoma and lung cancer in collaboration with Japanese Foundation for Cancer Research.

[Watch Video](#)

Participants

Presenter: Saori Mine - General Employee, API Co., Ltd

MediGear International Corporation

On demand
Startup Presentations

A startup to develop a cancer therapeutic nanodevice collaborating with Tokyo Tech, having a patent granted as PCT, now under pre-clinical test stage.

[View Pitch](#)

Past, Present, and Future of Auto-Injectors: Achieving Connectivity, Sustainability, Cost and Usability

On demand
Drug Delivery Partnerships Presentations

- Why disposable, single use autoinjectors, introduced in the early 2000s, can no longer satisfy today's requirements to reduce space, storage, and waste
- The growing demand for drug delivery device connectivity to improve patient adherence, care team collaboration, and health outcomes
- How pharmaceutical companies can create a clear path to low cost connectivity with more affordable, convenient, and sustainable injection devices
- Key considerations when embracing a connected health platform for biologic and injectable drugs

[Watch Video](#)

Participants

Speaker: Bill Welch - Chief Technology Officer, Phillips-Medisize

Speaker: Kevin Deane - Executive Vice President, Front-End Innovation, Phillips-Medisize, a Molex company

Apollo Life Sciences GmbH

On demand
BioPharm America Presentations

APLS is commercialising its flagship product, named genexyz, that allows quantification of 100 mRNAs simultaneously at a (sub)cellular resolution in situ with very high sensitivity. The technology is targeted towards pharma and academic researchers.

The technology platform provides unprecedented novel insights into the transcriptomic inventory of individual cells in any tissue sample with the spatial context intact. Thus, the technology allows to unravel root causes of various diseases by comparing healthy and disease tissues - for example, neurological disorders, tumour microenvironment, or infectious diseases such as SARS-CoV-2.

Given that the technology is applicable to almost any sample type (clinical tissue, model systems such as mouse, in vitro models such as organoids or cell cultures), it can be utilised for various biopharmaceutical applications. The technology is particularly of high interest to discover new biomarkers, drug targets, perform drug screening, and potentially develop novel diagnostic tools.

[Watch Video](#)

Participants

Presenter: Nachiket Kashikar - Head of Business Development, Service, and Commercial Operations, Apollo Life Sciences GmbH

Boston Pharmaceuticals

On demand
BioPharm America Presentations

Boston Pharmaceuticals is a translational drug development company. It was founded in 2016 by Chris Viehbacher, ex-CEO of Sanofi and Rob Armstrong, ex-R&D Executive from Eli Lilly. With \$600M committed capital from Gurnet Point Capital, Boston Pharma's business model is focused on partnering and developing therapeutics from late pre-clinical to clinical POC. In the past 4 years, we have built an experienced clinical development team and acquired a diverse portfolio of programs in oncology, autoimmune, cardiovascular, dermatology, anti-infective, gastrointestinal, and metabolic, including recent deals with GSK, Novartis, and other Pharma and biotech partners. In principle, we are agnostic with regards to indication or molecular modality. During this conference, we are seeking in licensing and out licensing partnering discussions.

[Watch Video](#)

Participants

Presenter: Constantine Chinoporos - CBO, Boston Pharmaceuticals

Dignify Therapeutics

On demand
BioPharm America Presentations

Dignify Therapeutics is a virtual drug development company focused on restoring voluntary control of excretory function to neurologically-impaired people. We operate as a lean, efficient organization with an aggressive approach to drug development. Our relationships with key opinion leaders in urology and gastroenterology provide access to the best individual care and clinical research centers in the world. This allows a fast, flexible and state-of-the-art clinical approach that will result in delivery of desperately needed new treatments to the market.

[Watch Video](#)

Participants

Presenter: Ed Burgard - President, Dignify Therapeutics

DTx Pharma

On demand - Coming Soon
BioPharm America Presentations

At DTx, we are creating novel RNA-based therapeutics to treat the genetic drivers of disease. Our proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In pre-clinical studies, we have demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells and many other specialized cell types.

Enzyvant

On demand
BioPharm America Presentations

Enzyvant, part of Sumitovant Biopharma (wholly owned by Sumitomo Dainippon Pharma), develops transformative therapies with urgency because speed matters for patients with rare diseases. With a focus on tissue-based regenerative therapies, Enzyvant is asteward of the science and a catalyst for change, helping to redefine best practices and capabilities in manufacturing, commercial and other areas needed to speed life-changing therapies to patients in desperate need. Enzyvant investigational therapies have received several regulatory designations including Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric Disease, and Orphan Drug designations by the FDA, as well as Advanced Therapy Medicinal Product (ATMP) classification and Orphan Drug designation by the European Medicines Agency. At Enzyvant, our work is inspired by patients, their battles with rare diseases and their hopes for the future. They are all the reasons for why, how and what we do.

[Watch Video](#)

Participants

Presenter: Rachelle Jacques - CEO, Enzyvant

GN Corporation Co Ltd

On demand
BioPharm America Presentations

Our core strength has been (i) Expertise in biomaterials and (ii) Networking among scientists of different domains and clinicians of various specialties to develop path-breaking solutions in healthcare.

Utilizing novel biomaterials available in Japan, we develop cell based therapies for application in Regenerative Medicine. Presently progress has been accomplished in Urology, Orthopedics and Ophthalmology

Our research in food supplements and core technologies in Japan have yielded exciting solutions to lifestyle diseases; Solutions to viral infections and cancer under progress.

We have got three patents granted in Japan and several pending in Japan and worldwide.

[Watch Video](#)

Participants

Presenter: Samuel JK Abraham - Head R&D, GN Corporation Co Ltd

SESSIONS

COMPANY PRESENTATIONS -

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Jaguar Health, Inc.

1:30am - 1:40am
BioPharm America Presentations

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit <https://jaguar.health>. For more information about Napo, visit www.napopharma.com.

[Watch Video](#)

Participants

Presenter: Lisa Conte - President and CEO, Jaguar Health, Inc.

Jubilant Therapeutics Inc

On demand
BioPharm America Presentations

Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company's leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB.

Jubilant Therapeutics exploits innovative discovery engine using structure based design, computational modelling and bio-informatics. Preclinical candidates have been identified for two lead programs with plans to go to Phase I in 12-18 months

1. Novel Dual inhibitors of LSD1/HDAC6 targeting cancer (AML, MDS, SCLC)

2. PAD4 inhibitors targeting auto-immune disorders (RA, Idiopathic Pulmonary Fibrosis)

3. Novel small molecule PD-L1 inhibitors

[Watch video](#)

Participants

Presenter: Syed Kazmi - President & CEO, Jubilant Therapeutics Inc

Maxwell Biosciences

On demand
BioPharm America Presentations

Maxwell Biosciences, Inc. was incorporated in January 2016 with the mission to prove Maxwell's patented "peptoid" drug class (Maxwell Peptoids™) as an effective and safe broad spectrum virucide in humans - an irreversibly antiviral drug. This is a world-first drug class that irreversibly inactivates humanity's top threat - highly infectious pandemic viruses. Maxwell's novel and patented anti-infectives have been shown by multiple independent labs (including Stanford, NYU and others) to be rapid killers of the world's deadliest and most contagious viral pathogens: Herpes Virus, SARS-CoV-2, Hepatitis viruses, and others. Preclinical lab tests show these potentially life-saving drugs are highly tolerated in mouse lungs, neurons, skin, gastrointestinal tract and cultured human cells. The drugs are remarkably effective at low doses evidencing a high probability for wide therapeutic windows in humans for multiple indications. The irreversible nature of the treatment, paired with independent, confirmed preclinical data showing safety in human tissues, make it a potentially game-changing therapeutic. Maxwell is raising funds for advanced preclinical and human trials for their lead product which targets the 75 million diagnosed Herpes Simplex HSV-1 cases with a topical ointment for chronic application.

Maxwell's patented drug class is a functional mimic - a small molecule biomimetic - of the peptide used by human white blood cells to attack viruses. This virus is known in literature as Human Cathelicidin Antimicrobial Peptide, CAMP, or LL-37. For over 200 million years, LL-37 has successfully defended primates against viruses without allowing viruses to develop significant resistance. Mimicking LL-37, our peptoids destroy the viral envelope and irreversibly entangle the nucleic acids of the virus, thereby inactivating the virus's ability to infect a cell.

Maxwell Biosciences recently announced confirmation by US Govt-funded labs that Maxwell's lead drug candidate has direct virucidal action against SARS-CoV-2, the COVID-19 virus. Additionally, recent live mouse safety data at Texas A&M show Maxwell's drugs benefit from a wide therapeutic window. These findings support the expected safety and effectiveness of Maxwell's broad-spectrum virucidal drug platform. Maxwell is led by a world-class team of experienced executives and scientists. Our business office is Headquartered in Austin, TX. Major research efforts are located in Palo Alto California, New York City, Louisville Kentucky, and Austin Texas.

[Watch Video](#)

Participants

Presenter: Joshua McClure - CEO, Maxwell Biosciences

MD Healthcare Inc.

On demand
BioPharm America Presentations

MD Healthcare Inc. is a microbiome-based precision medicine venture established in Seoul, South Korea in 2014. We have conducted metagenomic analysis of tens of thousands of clinical samples and found that microbial extracellular vesicles (EVs) are potent biomarkers for disease diagnosis and therapeutic agents. Using our proprietary microbial EV postbiotic technology, we are developing a variety of drug pipelines, diagnostic kits, and personalized healthcare services. By harnessing our microbial EV technology, we are developing pre-clinical core drug pipelines for immuno-oncology, respiratory, GI, skin, and CNS disease treatment in addition to AI-driven non-invasive diagnostic tools for various chronic diseases.

[Watch Video](#)

Participants

Presenter: Andrea McDowell - Business Development Specialist, MD Healthcare

Novadip Biosciences

On demand
BioPharm America Presentations

Novadip Biosciences is a clinical stage biopharmaceutical company leveraging its unique 3D tissue regeneration technology platform to generate multiple product candidates to address hard and soft tissue reconstruction for patients who have limited or no treatment options. The company's proprietary 3M3 platform is a 3-dimensional, extracellular matrix that utilizes adipose-derived stem cells to deliver highly-specific growth factors and miRNAs to mimic the physiology of natural healing and creates a range of products that address specific challenges in tissue regeneration.

Novadip's initial focus is on critical size bone reconstruction and its lead program is in development for a rare pediatric orthopedic disease. The company is also applying its 3M3 platform to develop truly novel off-the-shelf/allogeneic therapies to address more prevalent tissue defects and a cell-free miRNA exosome therapies for unattainable tissues.

[Watch Video](#)

Participants

Presenter: Denis Dufrane - CEO, Novadip Biosciences

Oligogen

On demand
BioPharm America Presentations

Oligogen, Inc. is a bio-venture company specializing in the R&D of cell therapy products using a new type of human neural stem cell, "OligoGenie". Our mission is to improve QOL of CNS diseases' patients and reduce burdens on family members by establishing a stem cell therapy method.

[Watch Video](#)

Participants

Presenter: Tsuneo Kido - Founder and CEO, Oligogen

Oligomerix Inc.

On demand
BioPharm America Presentations

Oligomerix has the potential to provide a transformational approach to treatment concerning Alzheimer's Disease and Dementia Related Disorders. The Company's novel and proprietary small molecule inhibitor and biomarker platform target the global unmet need of a successful therapeutic program for AD, which currently impacts more than 5.7 million Americans.

With more than 11 years of tau research experience and support from the National Institute on Aging at NIH, Oligomerix has developed a comprehensive package of novel CNS small molecule leads, biomarkers, and biotechnology that will help enable a de-risked, expedited clinical development program by a strategic partner.

[Watch Video](#)

Participants

Presenter: James Mo - President and CEO, Oligomerix Inc.

Oxidien Pharmaceuticals

On demand
BioPharm America Presentations

Oxidien Pharmaceuticals is a clinical stage drug development company. Using novel enzymes molecules we develop treatments for secondary hyperoxaluria, a large unmet medical need, to ultimately mitigate recurrent kidney stone disease. Secondary hyperoxaluria is a significant unmet need not only in rarer indications but also the general population. There are currently no approved therapies for any type of hyperoxaluria and we have an orally delivered, non-absorbed, best-in-class enzyme with exciting efficacy data and a favorable safety profile from a healthy volunteer study. Currently raising Series A to complete our first patient trial.

[Watch Video](#)

Participants

Presenter: Helena Cowley - President and CEO, Oxidien Pharmaceuticals

Ridgeline Therapeutics

On demand
BioPharm America Presentations

Ridgeline Therapeutics is a Houston-based biotechnology company developing safe and effective drugs that selectively target new mechanisms-of-action to reverse Type 2 diabetes, obesity, muscular dystrophies, and sarcopenia (age-related muscle degeneration).

[Watch Video](#)

Participants

Presenter: Stan Watowich - Founder and CEO, Ridgeline Therapeutics

Sengenics Corporation Pte Ltd

On demand
BioPharm America Presentations

Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarkers for two core medical use cases. Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events. Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

[Watch Video](#)

Participants

Presenter: Arif Anwar - CEO, Sengenics Corporation Pte Ltd

SmartTab

On demand
BioPharm America Presentations

SmartTab has developed a personalized wireless drug delivery platform comprised of an ingestible capsule with a microprocessor, proprietary smart polymer actuator, and active ingredients. We're on a mission to provide novel, effective therapies that improve patient outcomes and compliance.

[Watch Video](#)

Participants

Presenter: Robert Niichel - Founder and CEO, SmartTab

SESSIONS

COMPANY PRESENTATIONS -

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

TAE Life Sciences US LLC

On demand
BioPharm America Presentations

TAE Life Sciences is a biotechnology company focusing on R&D and commercialization of biologically-targeted radiation therapy based on boron neutron capture therapy (BNCT), an advanced technique for treating cancer. The outpatient treatment enables highly potent and conformal treatment for inoperable and difficult to treat cancers. It spares the surrounding healthy tissue and research has shown significant increase in survival compared to historical controls with minimal to no side effects systemic effects. In addition, the treatment can be completed in less than 60 min within a single session. In addition, the technology has been shown to be safe and effective for various types of cancers including ones that are radio- and chemo resistant.

[Watch Video](#)

Participants

Presenter: Bruce Bauer - CEO, TAE Life Sciences US LLC

Tsubota Laboratory, Inc.

On demand
BioPharm America Presentations

Our company is based at Keio University School of Medicine in Tokyo.

In 2017, our research group discovered and reported for the first time in the world that violet light (hereinafter VL) may suppress myopia progression. VL is light with a wavelength 360 to 400 nm and abundant in sunlight. Based on these various studies, we have been developing eyeglass-type medical equipment that emits VL in collaboration with JINS (One of the top eyeglass companies in Japan). Currently we are conducting clinical trials in Japan.

In addition, we found that VL is effective not only for myopia but also keratoconus, sleep quality, and gaining concentration, hoping to use this novel technology to save patients from these diseases in the world.

We have a number of international patents on VL and are ready to provide license for various applications.

We are also working on the development of other potential products in collaboration with Japanese pharmaceutical and manufacturing companies.

We hope to expand our business outside of Japan and are looking for a local business partner that handles clinical trials and sells products.

[Watch Video](#)

Participants

Presenter: Ryo Konno - Business Development Manager, Tsubota Laboratory, Inc.

SCHEDULE

COMPANY PRESENTATIONS -

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

TIME	BIOPHARM AMERICA PRESENTATIONS	DRUG DELIVERY PARTNERSHIPS PRESENTATIONS	STARTUP PRESENTATIONS
12:00AM	<p>On demand - Agilex Biolabs</p> <p>On demand - Anima Biotech</p> <p>On demand - API Co., Ltd</p> <p>On demand - Apollo Life Sciences GmbH</p> <p>On demand - Boston Pharmaceuticals</p> <p>On demand - Dignify Therapeutics</p>	<p>On demand - Aprecia - Delivering the Next Generation of Medicine Today</p> <p>On demand - Key Tech & Matchstick - Foundational Methods to Confidently Freeze Complex Delivery Device Architectures</p> <p>On demand - Past, Present, and Future of Auto-Injectors: Achieving Connectivity, Sustainability, Cost and Usability</p>	<p>On demand - ARDAN PHARMA</p> <p>On demand - Ciscovey Bio Inc</p> <p>On demand - Element Therapeutics Company</p> <p>On demand - EndoCrine</p> <p>On demand - MediGear International Corporation</p>
1:00AM	<p>On demand - Coming Soon - DTx Pharma</p> <p>On demand - Enzyvant</p> <p>On demand - GN Corporation Co Ltd</p> <p>1:30am - Jaguar Health, Inc.</p> <p>On demand - Jubilant Therapeutics Inc</p> <p>On demand - Maxwell Biosciences</p>		
2:00AM	<p>On demand - MD Healthcare Inc.</p> <p>On demand - Novadip Biosciences</p> <p>On demand - Oligogen</p> <p>On demand - Oligomerix Inc.</p> <p>On demand - Oxidien Pharmaceuticals</p> <p>On demand - Ridgeline Therapeutics</p>		
3:00AM	<p>On demand - Sengenics Corporation Pte Ltd</p> <p>On demand - SmartTab</p> <p>On demand - TAE Life Sciences US LLC</p> <p>On demand - Tsubota Laboratory, Inc.</p>		

SESSIONS

DAY 1 - 21/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Master Class A, part 1: Alliance management - concepts and tools to make the best out of your partnerships (available On Demand)

9:00am - 9:30am
Drug Delivery Partnerships

Strategic alliances have a growing importance in most companies, both large and small, and have significant influence on long-term corporate success. At the same time these collaborative relationships between partners with often significant organizational and cultural differences are frequently challenging and complex, and therefore require careful and diligent management for maximum impact.

In this half-day interactive workshop key concepts and tools to address the various parts of the alliance lifecycle, from alliance strategy to search, negotiation, launch, working and closing phase, are discussed.

[Watch Master Class](#)

Participants

Speaker: Christoph Huwe - Director, Strategic Alliance Management, Bayer

Master Class A, part 2: Alliance management - concepts and tools to make the best out of your partnerships (available On Demand)

9:30am - 10:15am
Drug Delivery Partnerships

Strategic alliances have a growing importance in most companies, both large and small, and have significant influence on long-term corporate success. At the same time these collaborative relationships between partners with often significant organizational and cultural differences are frequently challenging and complex, and therefore require careful and diligent management for maximum impact.

In this half-day interactive workshop key concepts and tools to address the various parts of the alliance lifecycle, from alliance strategy to search, negotiation, launch, working and closing phase, are discussed.

[Watch Master Class](#)

Participants

Speaker: Christoph Huwe - Director, Strategic Alliance Management, Bayer

Master Class A, part 3: Alliance management - concepts and tools to make the best out of your partnerships (available On Demand)

10:15am - 11:00am
Drug Delivery Partnerships

Strategic alliances have a growing importance in most companies, both large and small, and have significant influence on long-term corporate success. At the same time these collaborative relationships between partners with often significant organizational and cultural differences are frequently challenging and complex, and therefore require careful and diligent management for maximum impact.

In this half-day interactive workshop key concepts and tools to address the various parts of the alliance lifecycle, from alliance strategy to search, negotiation, launch, working and closing phase, are discussed.

[Watch Master Class](#)

Participants

Speaker: Christoph Huwe - Director, Strategic Alliance Management, Bayer

What will AI actually solve in the next 5–10 years? (available On Demand)

10:30am - 10:50am
AI Applications for Drug Discovery Development

- Landscape, regulatory and business overview
- High-level summary of use cases
- Where should investment be made and what could be the best strategic decisions?

[Watch Presentation](#)

Participants

Speaker: Emir Roach - Global Head of Emerging Technologies and Digital Health Partnerships, Takeda

What does precision medicine actually mean and how can AI and ML impact it? (available On Demand)

11:00am - 11:40am
AI Applications for Drug Discovery Development

Precision medicine is a medical model that can customize healthcare, treatments, practices or products for the individual patient. In this discussion our experts will explore AI and ML's impact on Precision medicine and what the industry needs to do to prepare for it, tackle challenges as they evolve and develop appropriate solutions.

- How this industry is using AI and ML for Precision medicine
- What can we really use it for
- What problems we are trying to solve using these tools, and what impacts they will have on those problem

[Watch Panel](#)

Participants

Moderator: Monique Levy - Chief Strategy & Commercial Officer, Woebot Health

Panelist: Renee Deehan - VP Computational Biology, Quartz Bio

Panelist: Colin Hill - Chairman, CEO and Co-Founder, GNS Healthcare

Panelist: Tanya Wallace - Head of Biology, Blackthorn Therapeutics

Master Class A, part 4: Alliance management - concepts and tools to make the best out of your partnerships (available On Demand)

11:00am - 11:30am
Drug Delivery Partnerships

Strategic alliances have a growing importance in most companies, both large and small, and have significant influence on long-term corporate success. At the same time these collaborative relationships between partners with often significant organizational and cultural differences are frequently challenging and complex, and therefore require careful and diligent management for maximum impact.

In this half-day interactive workshop key concepts and tools to address the various parts of the alliance lifecycle, from alliance strategy to search, negotiation, launch, working and closing phase, are discussed.

[Watch Master Class](#)

Participants

Speaker: Christoph Huwe - Director, Strategic Alliance Management, Bayer

SESSIONS

DAY 1 - 21/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Fireside Chat: Using AI to optimize drug selection and development (available On Demand)

11:45am - 12:05pm

AI Applications for Drug Discovery Development

- Predictive drug efficacy
- Radiology & image recognition
- Remove subjectivity from trial data

[Watch Fireside Chat](#)

Participants

Host: John Vandermosten - Senior Biotechnology Analyst, Zacks Investment Research

Guest: Panna Sharma - CEO, Lantern Pharma

Master Class B: Parts 1 & 2 – Negotiation for Drug Delivery (available On-Demand) – Please view these prior to joining the LIVE Part 3

12:00pm - 2:15pm

Drug Delivery Partnerships

Drug delivery innovations have the potential to create significant value and their successful delivery to the market depends on the seamless collaboration between multiple parties. All major stakeholders in the innovation process will typically engage in multiple negotiations along the way from the first ideation of a novel product to its market introduction and beyond. These negotiations often span various areas including product profile, timelines, funding, and distribution of the value created.

The interactive half-day master class provides an overview of proven negotiation practices and illustrates how to apply these in the dynamic environment of drug delivery innovation.

[Watch Master Class B, part 1](#)

[Watch Master Class B, part 2](#)

Participants

Speaker: Ralph Lipp - President and CEO, Lipp Life Sciences

Conversational AI and Voice Assistance (available On Demand)

12:05pm - 12:25pm

AI Applications for Drug Discovery Development

- Chat bots and conversational AI – role these can play in patient and investigator support as well as trial adherence
- How can bots help patients find the trials they are eligible for?
- Natural language understanding and sentiment
- HIPAA, GDPR, privacy compliance for voice
- Target demographics (patient types) for voice, diversity (accents), avoiding bias
- Deployment, maintenance of tech (especially in-home)

[Watch Interview](#)

Participants

Host: Stephen Ruhmel - Associate Director, Janssen Clinical Innovation, Johnson & Johnson, USA

Guest: Timothy Chen - Mobile Health Director, Medidata

Opening the black box: AI design for actionable and verifiable drug target prediction (available On Demand)

1:00pm - 1:20pm

AI Applications for Drug Discovery Development

- How are people validating the decisions made by AI?
- If we can provide better experimentally validated targets – will drug discovery become more valuable?
- Would better validation lead to re-risking the development process?

[Watch Presentation](#)

Participants

Speaker: Martin Akerman - Co-Founder and CTO, Envisagenics

AI for clinical trial design - failing fast to succeed faster (available On Demand)

1:20pm - 1:40pm

AI Applications for Drug Discovery Development

- Can the central dogma of clinical trials be challenged?
- How can the clinical trials process be made more efficient? Overcoming barriers and enabling better outcomes
- Using RWE to leverage trial design and predict outcomes
- Clinical trial models, i.e., Hybrid, etc.

[Watch Presentation](#)

Participants

Speaker: Colin Hill - Chairman, CEO and Co-Founder, GNS Healthcare

Live Speaker Q&A

1:40pm - 2:25pm

AI Applications for Drug Discovery Development

Join Speakers from the AI Applications For Drug Discovery and Development track for a live in person Q&A session. Use this opportunity to connect with program participants as well as other attendees.

[Join Live Q&A](#)

LIVE: Master Class B, part 3: Negotiation for drug delivery innovation

2:15pm - 3:00pm

Drug Delivery Partnerships

Drug delivery innovations have the potential to create significant value and their successful delivery to the market depends on the seamless collaboration between multiple parties. All major stakeholders in the innovation process will typically engage in multiple negotiations along the way from the first ideation of a novel product to its market introduction and beyond. These negotiations often span various areas including product profile, timelines, funding, and distribution of the value created.

The interactive half-day master class provides an overview of proven negotiation practices and illustrates how to apply these in the dynamic environment of drug delivery innovation.

In Part 4, participants will debrief the group about their negotiation outcomes. Ralph will discuss learnings, summarize key points and answer potential questions.

Please note: The Master Class Live Q&A session is invitation-only and can only be accessed through the link sent directly to you. If you have opted into the Master Class and think you should have access, please get in touch with Danica Schroth (Danica.Schroth@informa.com) and Paige Santillo (Paige.Santillo@informa.com).

Participants

Speaker: Ralph Lipp - President and CEO, Lipp Life Sciences

SCHEDULE

DAY 1 - 21/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

TIME	AI APPLICATIONS FOR DRUG DISCOVERY DEVELOPMENT	DRUG DELIVERY PARTNERSHIPS
9:00AM		<p>9:00am - Master Class A, part 1: Alliance management - concepts and tools to make the best out of your partnerships (available On Demand)</p> <p>9:30am - Master Class A, part 2: Alliance management - concepts and tools to make the best out of your partnerships (available On Demand)</p>
10:00AM	<p>10:30am - What will AI actually solve in the next 5–10 years? (available On Demand)</p>	<p>10:15am - Master Class A, part 3: Alliance management - concepts and tools to make the best out of your partnerships (available On Demand)</p>
11:00AM	<p>11:00am - What does precision medicine actually mean and how can AI and ML impact it? (available On Demand)</p> <p>11:45am - Fireside Chat: Using AI to optimize drug selection and development (available On Demand)</p>	<p>11:00am - Master Class A, part 4: Alliance management - concepts and tools to make the best out of your partnerships (available On Demand)</p>
12:00PM	<p>12:05pm - Conversational AI and Voice Assistance (available On Demand)</p>	<p>12:00pm - Master Class B: Parts 1 & 2 – Negotiation for Drug Delivery (available On-Demand) – Please view these prior to joining the LIVE Part 3</p>
1:00PM	<p>1:00pm - Opening the black box: AI design for actionable and verifiable drug target prediction (available On Demand)</p> <p>1:20pm - AI for clinical trial design - failing fast to succeed faster (available On Demand)</p> <p>1:40pm - Live Speaker Q&A</p>	
2:00PM		<p>2:15pm - LIVE: Master Class B, part 3: Negotiation for drug delivery innovation</p>

SESSIONS

DAY 2 - 22/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Registration & Networking Lounge Open

9:00am - 9:10am
LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Opening remarks

9:10am - 9:20am
LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Speaker: Wendy Nelson - CEO & President Leading Biotech, Boston, Leading Biotech

Speaker: Robert Perez - Founder and Chairperson, Life Science Cares

The role of patient advocacy groups and disease foundations in our ecosystem

9:20am - 10:05am
LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Moderator: Chris Garabedian - CEO, Xontogeny

Panelist: Jenn McNary - Founder, One Rare

Panelist: Michele Rhee - Patient Affairs, Enzyvant

Moderator: Samantha Singer - Entrepreneur-In-Residence, Third Rock Ventures

Top considerations when engaging a potential strategic partnership

10:05am - 10:35am
LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Panelist: Chandra Ramanathan - Global Head, Pharma R&D Open Innovation, Bayer

Panelist: Steve Tregay - Managing Partner, BioInnovation Capital

Panelist: Patrick Tricoli - CEO, Nanobiotix US and Global Head of Business Development, Nanobiotix

Moderator: Daniela Iwanski - Vice President, Executive Recruiter, Govig & Associates

Fireside chat: Maximizing value in an M&A

10:35am - 11:00am
LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Speaker: Gary Glick - Founder and Executive Chair, IFM

Moderator: Wendy Nelson - CEO & President Leading Biotech, Boston, Leading Biotech

CSTD Regulatory Considerations (available On Demand)

10:40am - 11:00am
Drug Delivery Partnerships

[Watch Presentation](#)

Participants

Speaker: Lana Shiu - Executive Director, Medical Device Regulatory Affairs, Global Regulatory Affairs and Safety, Amgen

Spotlight: Gingko Bioworks

11:00am - 11:15am
LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Speaker: Jason Kelly - Co- Founder & CEO, Gingko Bioworks

Regulatory and scientific justifications for CMC Changes - Case studies of modified release products (available On Demand)

11:00am - 11:20am
Drug Delivery Partnerships

A drug product rarely remains unchanged throughout its lifecycle. When changes in raw materials, formulation, process, shelf-life, specification or test methods are needed during product development or commercialization, it is essential to evaluate and understand the potential impacts of these changes on the quality, safety and efficacy of the product. To ensure quality and performance, an array of law, regulations and guidelines need to be followed. In addition, scientific justifications based on product and process understanding can also play an important role, especially when changes are outside of the prescriptive regulatory guidance. This presentation will discuss regulatory requirements and scientific justifications that can be used to support different CMC changes for modified release products, including examples of justifying specification revision, multiple related formulation and process changes and biowaivers based on both quantitative and qualitative in vitro-in vivo relationship.

[Watch Presentation](#)

Participants

Speaker: Yihong Qiu - Senior Research Fellow, Formulation Sciences, Abbvie

Fireside chat: Pricing

11:15am - 12:00pm
LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Speaker: Bruce Booth - Partner, Atlas Venture

Speaker: Andy Plump - President, R&D, Takeda Pharmaceutical Co., Ltd.

EU/MDR/IVDR combination product and companion product considerations

11:20am - 11:40am
Drug Delivery Partnerships

[Watch Presentation](#)

Participants

Speaker: Liliana Omar - Regulatory and Quality Project Director, Covance

Lunch Break & Networking Lounge

12:00pm - 12:30pm
LeadingBiotech BD & CEO USA

[Click here to enter session](#)

SESSIONS

DAY 2 - 22/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Keynote: Innovating Beyond Reason

12:30pm - 1:00pm

LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Speaker: Noubar Afeyan - Founder & CEO, Flagship Pioneering

Diversity and inclusion: Cultivating the next generation of biotech execs

1:00pm - 1:45pm

LeadingBiotech BD & CEO USA

What can we do as an industry to cultivate the next generation of leaders and innovators and encourage diversity (beyond just gender diversity) while doing so?

[Click here to enter session](#)

Participants

Panelist: Barbara Fox - CEO, Rheos Medicines

Panelist: Daniel Lynch - Chairperson of the Board, Surface Oncology

Panelist: Adelene Perkins - CEO, Infinity Pharmaceuticals

Panelist: Jennifer Petter - Founder and CSO, Arrakis Therapeutics

Moderator: Robert Perez - Founder and Chairperson, Life Science Cares

Fireside chat: The mentor/mentee relationship

1:45pm - 2:15pm

LeadingBiotech BD & CEO USA

How does an entrepreneur find a mentor? What does such a relationship look like and how to ensure each party gets the most out of it?

[Click here to enter session](#)

Participants

Speaker: Michael Bonney - Executive Chair, Kaleido Biosciences

Speaker: Carrie Bourdow - CEO, Trevena

Moderator: Wendy Nelson - CEO & President Leading Biotech, Boston, Leading Biotech

To go IPO or remain private?

2:15pm - 2:45pm

LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Panelist: Ankit Mahadevia - CEO, Spero Therapeutics

Panelist: Brian McVeigh - CBO, Zafgen

Panelist: Donald Nicholson - Former CEO, Nimbus Therapeutics

Moderator: Marian Nakada - VP, Venture Investments, Johnson & Johnson Innovation

Building your biotech: From the ground up

2:45pm - 3:15pm

LeadingBiotech BD & CEO USA

What does it take to get your company up and running? What pitfalls do you want to avoid? Lessons learned from those that have done it!

[Click here to enter session](#)

Participants

Moderator: Carolyn Morgan - CEO, Precision Effect

Panelist: PJ Anand - Founder and CEO, Alcyone Lifesciences

Panelist: Jodie Morrison - CEO, Cadent Therapeutics

Panelist: Bernat Olle - CEO, Vedanta Biosciences

New players in the healthcare space

3:15pm - 3:45pm

LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Panelist: Sean Burke - former CCO, GE Healthcare

Panelist: Zen Chu - Founder, Feelcov

Panelist: Imran Eba - Partner, Action Potential Capital

Moderator: Arthur Hiller - Independent Consultant and Chief Business Officer, Nuritas

The convergence of AI and medicine

3:45pm - 4:15pm

LeadingBiotech BD & CEO USA

[Click here to enter session](#)

Participants

Panelist: Vik Bajaj - Managing Director, Foresite Capital Management

Panelist: Anne Heatherington - Sr. VP and Head of Data Sciences Institute (DSI) with Research and Development, Takeda Pharmaceuticals

Panelist: Iya Khalil - Global Head of the AI Innovation Center, Novartis

Moderator: Jennifer Lum - Managing Partner, Biospring Partners

Closing Remarks & Virtual Cocktail Party

4:15pm - 5:00pm

LeadingBiotech BD & CEO USA

[Click here to enter session](#)

SCHEDULE

DAY 2 - 22/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

TIME	DRUG DELIVERY PARTNERSHIPS	LEADINGBIOTECH BD & CEO USA
9:00AM		<p>9:00am - Registration & Networking Lounge Open</p> <p>9:10am - Opening remarks</p> <p>9:20am - The role of patient advocacy groups and disease foundations in our ecosystem</p>
10:00AM	<p>10:40am - CSTD Regulatory Considerations (available On Demand)</p>	<p>10:05am - Top considerations when engaging a potential strategic partnership</p> <p>10:35am - Fireside chat: Maximizing value in an M&A</p>
11:00AM	<p>11:00am - Regulatory and scientific justifications for CMC Changes - Case studies of modified release products (available On Demand)</p> <p>11:20am - EU/MDR/IVDR combination product and companion product considerations</p>	<p>11:00am - Spotlight: Gingko Bioworks</p> <p>11:15am - Fireside chat: Pricing</p>
12:00PM		<p>12:00pm - Lunch Break & Networking Lounge</p> <p>12:30pm - Keynote: Innovating Beyond Reason</p>
1:00PM		<p>1:00pm - Diversity and inclusion: Cultivating the next generation of biotech execs</p> <p>1:45pm - Fireside chat: The mentor/mentee relationship</p>
2:00PM		<p>2:15pm - To go IPO or remain private?</p> <p>2:45pm - Building your biotech: From the ground up</p>
3:00PM		<p>3:15pm - New players in the healthcare space</p> <p>3:45pm - The convergence of AI and medicine</p>
4:00PM		<p>4:15pm - Closing Remarks & Virtual Cocktail Party</p>

SESSIONS

DAY 3 - 23/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Welcome Remarks (available On Demand)

10:25am - 10:30am
Drug Delivery Partnerships

[Watch Welcome Remarks](#)

Participants

Speaker: Sridharan - Group Director, Materials Science & Engineering, Bristol-Myers Squibb

What are the big questions AI can help answer and what's holding us back? (available On Demand)

10:30am - 10:50am
AI Applications for Drug Discovery Development

- Provide examples of opportunities for AI in pharma/biotech
- Share the challenges that Pfizer and industry are facing in adopting AI
- Discuss strategies for moving forward and transforming R&D

[Watch Presentation](#)

Participants

Speaker: Peter Henstock - Machine Learning & AI Technical Lead, Pfizer

Patient-focused drug delivery - the view from a new player (available On Demand)

10:30am - 10:50am
Drug Delivery Partnerships

[Watch Presentation](#)

Participants

Speaker: Vlad Coric, MD - CEO and Director, Biohaven Pharmaceuticals

Portfolio management and business models (available On Demand)

10:50am - 11:10am
AI Applications for Drug Discovery Development

- Focus on discovery for many to build IP and attract investment – is this where the economic payoff is?
- What is the best model to use? Develop a platform, or develop a pipeline?
- Financing and Investor Models
- How do traditional pharma position themselves vs. the new emerging companies getting into the healthcare space?
- Where do small companies vs. larger companies focus energies?
- What partnerships are the most valuable?

[Watch Presentation](#)

Participants

Speaker: Ed Addison - CEO, Cloud Pharmaceuticals

Innovate inside the box: Challenges and considerations when customizing a platform delivery device (available On Demand)

11:10am - 11:30am
Drug Delivery Partnerships

A well-considered drug delivery system can maximize the effectiveness of innovative small molecule and biologic therapies. But how do you choose the best system for your drug? Do you choose a cost-effective, off-the-shelf platform or invest in developing a custom drug delivery device? There are pros and cons for each option—and there is also a third path to consider. Adapting an existing platform device with a few custom attributes tailored to your molecule can offer the best of both worlds.

[Watch Presentation](#)

Participants

Speaker: Doug Boyd - Manager, Medical Device Solutions, Battelle

Live: Building a data foundation for AI and ML applications

1:00pm - 1:20pm
AI Applications for Drug Discovery Development

- How a strategy/foundation can be built to enable AI
- What can be built to determine models needed
- What data can drive

[Join Live Presentation](#)

Participants

Speaker: Patrick Combes - WW Technical Leader - Healthcare & Life Sciences, Amazon Web Services

Case study: Alleviating challenges of oral peptide delivery (available On Demand)

1:00pm - 1:20pm
Drug Delivery Partnerships

This talk will cover some unique strategies to alleviate challenges of oral peptide delivery. Pre-clinical data from a recent case study will be shared.

[Watch Case Study](#)

Participants

Speaker: Aktham Aburub - Research Fellow, Product Design & Development, Eli Lilly

Responsible AI and machine learning for drug discovery and development (available On Demand)

1:20pm - 1:55pm
AI Applications for Drug Discovery Development

- What credibility and assessments for an AI system
- Data exploration as it feeds into AI and Machine Learning systems
- Oversight of the data, algorithms and overall systems

[Watch Panel](#)

Participants

Moderator: Arvind Rao - Associate Professor, Department of Computational Medicine & Bioinformatics, Radiation Oncology, University of Michigan Medical School

Panelist: Nirmal Keshava - VP, Data Analytics and Innovation Science, Cerevel Therapeutics

Panelist: Ashwini Ghogare - Manager, AI-Enabled Drug Discovery, Global Strategy Group, MilliporeSigma

Panelist: Abe Heifets - CEO and Co-Founder, Atomwise

Case Study: Creating a Connected Platform for Pre-Filled Syringes While Minimizing Cost (available On Demand)

1:20pm - 1:40pm
Drug Delivery Partnerships

The opportunities and challenges of co-designing a platform for smart injector pens that can be adapted depending on the drug, and that tracks injections and transmits data to mobile phones and clinical web applications.

[Watch Case Study](#)

Participants

Speaker: Yossef Schvets - Director, Industrial Design and Use Experience, flex

SESSIONS

DAY 3 - 23/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Brain delivery of biologics – VIA cerebrospinal fluid (available On Demand)

1:20pm - 1:40pm
Drug Delivery Partnerships Track 2

Brain delivery of biologics such as antibodies and nucleic acid therapeutics via the intravenous (IV) route results in limited partitioning to the brain due the blood-brain barrier (BBB). The cerebrospinal fluid (CSF) may provide a better access point to brain by bypassing the BBB. The talk outlines literature –reported as well as more recent findings on impact of CSF access location and delivery flow rates on distribution of biologics to different brain regions.

[Watch Presentation](#)

Participants

Speaker: Shraddha Sadekar - Scientist, PKPD, Genentech

Advancing towards clinical use of innovative dual chamber technology to deliver cutting-edge therapies treating immune-mediated disorders (available On Demand)

1:40pm - 2:00pm
Drug Delivery Partnerships

[Watch Presentation](#)

Participants

Speaker: Evan Lewis - Senior Director, Pharmaceutical Development, Kezar Life Sciences

Speaker: John Merhige - CCO, Credence MedSystems

Live Speaker Q&A

1:55pm - 2:40pm
AI Applications for Drug Discovery Development

Join Speakers from the AI Applications For Drug Discovery and Development track for a live in person Q&A session. Use this opportunity to connect with program participants as well as other attendees.

[Join Live Q&A](#)

Participants

Host: Arvind Rao - Associate Professor, Department of Computational Medicine & Bioinformatics, Radiation Oncology, University of Michigan Medical School

Connectivity in drug delivery – strategies from the leaders of the pack (available On Demand)

2:00pm - 2:30pm
Drug Delivery Partnerships

[Watch Panel](#)

Participants

Moderator: Yasemin Karanis - Consultant, Thought Leadership, IQVIA

Panelist: David Braun - Global Head, Connected Health and Medical Device Solutions, Merck Healthcare

Panelist: Christopher Kovalchick - Director, Mechanical Engineering, Eli Lilly and Company

Panelist: Terry Reed - Director, Business Development, AstraZeneca

Learning and challenges: Release testing and simulations for long acting parenteral products (available On Demand)

2:00pm - 2:30pm
Drug Delivery Partnerships Track 2

[Watch Presentation](#)

Participants

Speaker: Manuel Sanchez-Felix - Senior Fellow, Novel Delivery Technologies, Novartis Institutes for BioMedical Research (NIBR)

Live Speaker Q&A

2:30pm - 3:15pm
Drug Delivery Partnerships

Join program participants and other attendees for this moderated Q&A session

[Join Live Q&A](#)

Participants

Host: Sridharan - Group Director, Materials Science & Engineering, Bristol-Myers Squibb

SCHEDULE

DAY 3 - 23/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

TIME	AI APPLICATIONS FOR DRUG DISCOVERY DEVELOPMENT	DRUG DELIVERY PARTNERSHIPS	DRUG DELIVERY PARTNERSHIPS TRACK 2
10:00AM	<p>10:30am - What are the big questions AI can help answer and what's holding us back? (available On Demand)</p> <p>10:50am - Portfolio management and business models (available On Demand)</p>	<p>10:25am - Welcome Remarks (available On Demand)</p> <p>10:30am - Patient-focused drug delivery - the view from a new player (available On Demand)</p>	
11:00AM		<p>11:10am - Innovate inside the box: Challenges and considerations when customizing a platform delivery device (available On Demand)</p>	
12:00PM			
1:00PM	<p>1:00pm - Live: Building a data foundation for AI and ML applications</p> <p>1:20pm - Responsible AI and machine learning for drug discovery and development (available On Demand)</p> <p>1:55pm - Live Speaker Q&A</p>	<p>1:00pm - Case study: Alleviating challenges of oral peptide delivery (available On Demand)</p> <p>1:20pm - Case Study: Creating a Connected Platform for Pre-Filled Syringes While Minimizing Cost (available On Demand)</p> <p>1:40pm - Advancing towards clinical use of innovative dual chamber technology to deliver cutting-edge therapies treating immune-mediated disorders (available On Demand)</p>	<p>1:20pm - Brain delivery of biologics – VIA cerebrospinal fluid (available On Demand)</p>
2:00PM		<p>2:00pm - Connectivity in drug delivery – strategies from the leaders of the pack (available On Demand)</p> <p>2:30pm - Live Speaker Q&A</p>	<p>2:00pm - Learning and challenges: Release testing and simulations for long acting parenteral products (available On Demand)</p>

SESSIONS

DAY 4 - 24/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Welcome Remarks (available On Demand)

10:25am - 10:30am
Drug Delivery Partnerships

[Watch Welcome Remarks](#)

Participants

Speaker: Joshua Horvath - Director, Early Stage Devices and Human Factors Engineering, Genentech

AI and genomic approaches to diagnostics in the rare-disease space (available On Demand)

10:30am - 10:50am
AI Applications for Drug Discovery Development

[Watch Presentation](#)

Participants

Speaker: Sebastien Lefebvre - Senior Director - Data Sciences, Genomics and Bioinformatics, Alexion

De-risking partnerships – Best practices to working with start-ups, pharma, and novel technologies (available On Demand)

10:55am - 11:25am
Drug Delivery Partnerships

"Innovation ecosystems—the collaborative arrangements through which firms combine their individual offerings into a coherent, customer-facing solution. When they work, ecosystems allow firms to create value that no single firm could have created alone." HBR, Match Your Innovation Strategy to Your Innovation Ecosystem

Why should big pharma companies partner for drug delivery? What are the concerns that pharma companies have when considering partnering, especially with small firms or innovative technologies? How can those concerns be de-risked in a mutually beneficial way for both the pharma firm and the start-up? What makes a successful partnership work?

This panel discussion will take a look at risks specific to drug delivery partnerships; best practices for mitigating risks to ensure success, and key success factors for partnerships;

Discussion points include:
Benefits to partnering
Perceived and real risks to partnering for drug delivery
Establishing successful partnerships
Bottlenecks that are still common today and strategies for solving them
Note that while this panel topic has been discussed at many events, the focus at DDP will be to provide some innovative best practices and lessons learned from more recent partnerships, and also discuss bottlenecks that are still common along with unique strategies to work through them.

[Watch Panel](#)

Participants

Moderator: Patrick Anquetil - CEO, Portal Instruments, Inc.

Panelist: Mindy Katz - Director of Product, Sorrel Medical

Panelist: Stefan Koenig - Global Program & Brand Lead, Takeda

Panelist: John Merhige - CCO, Credence MedSystems

Privacy: Data and consent in the drug development lifecycle – Regulatory compliance and ethics frameworks in the application of AI and ML (available On Demand)

11:30am - 12:00pm
AI Applications for Drug Discovery Development

- HIPAA Compliance – what will this involve/mean moving forward?
- Patient consent as linked to data privacy
- Data sharing-Include representatives from: Integrated healthcare delivery systems, insurance, privacy, and pharma

[Watch Panel](#)

Participants

Moderator: Kathleen Snyder - Technology Transactions Group, Wilson Sonsini Goodrich & Rosati

Panelist: Kevin Hua - Senior Manager AI/Machine Learning Development, Bayer

Panelist: Faisal Khan - Executive Director, Advanced Analytics and Artificial Intelligence, AstraZeneca

Pandemic prevention through gene therapy delivery (available On Demand)

11:40am - 12:00pm
Drug Delivery Partnerships

The Defense Advanced Research Projects Agency (DARPA) has issued a bold goal of developing a functionally integrated platform to deliver 20,000 doses of a pandemic prevention treatment in less than 60 days from the identification of the threat. To address this challenge, AstraZeneca has developed multiple In Vivo Expressed Biologic modalities providing robust protection for weeks to months in various animal models. This presentation will focus on the development and delivery of an mRNA construct coding for an anti-influenza monoclonal antibody and present early pre-clinical evidence of its efficacy.

[Watch Presentation](#)

Participants

Speaker: Shawn Davis - Senior Director, Head of Drug Delivery, AstraZeneca

Live Speaker Q&A

12:20pm - 12:50pm
AI Applications for Drug Discovery Development

Join Speakers from the AI Applications For Drug Discovery and Development track for a live in person Q&A session. Use this opportunity to connect with program participants as well as other attendees.

[Join Live Q&A](#)

SESSIONS

DAY 4 - 24/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

Technological advances to address oral delivery of challenging molecules (available On Demand)

1:00pm - 1:20pm
Drug Delivery Partnerships

Since the advent of controlled release technologies, several advancements have been made to maximize the therapeutic effect of drug molecules. Despite these developments, there are still several gaps especially for compounds that show site specific absorption or require drug to release at certain time of the day to improve the therapeutic outcome.

Recent advancements utilizing more robust drug delivery systems based on gastro-retentive delivery system and chronological delivery of drugs have been made to address the needs of such challenging molecules.

This presentation will cover the differentiating features of these next generation technologies and therapeutic utility for a wide range of molecules and disease conditions. We will present case studies of example drugs in clinical development using these technologies and describe how they can potentially improve the drug's efficacy and tolerability.

[Watch Presentation](#)

Participants

Speaker: Pavan Handa - Senior VP, Business Development & Strategy, Kashiv BioSciences

Coming Soon - Linking the device to the patient (available On Demand)

1:00pm - 1:20pm
Drug Delivery Partnerships Track 2

Participants

Speaker: Uri Baruch - Head of Drug Delivery, Cambridge Design Partnership

Connectivity and Devices (available On Demand)

1:20pm - 1:40pm
Drug Delivery Partnerships

Sensile Medical has developed a patchpump for delivery based upon a 3ml cartridge for two very different therapies: (1) Furosemide for CHF therapy and (2) Insulin for Diabetes therapy. The presentation discusses how one platform and its development can accommodate the very different therapy needs in question.

[Watch Presentation](#)

Participants

Speaker: Amir Tahric - VP, Business Development, Sensile Medical AG

Speaker: David Christen - Head Software Development and Application Software Engineering, Sensile Medical

Live Speaker Q&A

2:00pm - 2:45pm
Drug Delivery Partnerships Track 2

Join program participants and other attendees for this moderated Q&A session.

[Join Live Q&A](#)

Participants

Host: Joshua Horvath - Director, Early Stage Devices and Human Factors Engineering, Genentech

SCHEDULE

DAY 4 - 24/09/2020

BioPharm America - Virtual

September 21–24, 2020

Proudly part of Biotech Week Boston
Delivered Digitally | US Eastern Daylight Time

TIME	AI APPLICATIONS FOR DRUG DISCOVERY DEVELOPMENT	DRUG DELIVERY PARTNERSHIPS	DRUG DELIVERY PARTNERSHIPS TRACK 2
10:00AM	10:30am - AI and genomic approaches to diagnostics in the rare-disease space (available On Demand)	10:25am - Welcome Remarks (available On Demand) 10:55am - De-risking partnerships – Best practices to working with start-ups, pharma, and novel technologies (available On Demand)	
11:00AM	11:30am - Privacy: Data and consent in the drug development lifecycle – Regulatory compliance and ethics frameworks in the application of AI and ML (available On Demand)	11:40am - Pandemic prevention through gene therapy delivery (available On Demand)	
12:00PM	12:20pm - Live Speaker Q&A		
1:00PM		1:00pm - Technological advances to address oral delivery of challenging molecules (available On Demand) 1:20pm - Connectivity and Devices (available On Demand)	1:00pm - Coming Soon - Linking the device to the patient (available On Demand)
2:00PM			2:00pm - Live Speaker Q&A